Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation (501Y.V2 lineage, B.1.351; P.1 lineage, B.220.127.116.11; Kent variant; B.1.526 lineage)
Cat No.: GMP-V-2019nCoV-Smu-017
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Package||Catalog No.||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Expression platform||2019-nCoV(SARS-CoV-2, SARS2-coronavirus)|
|Isotypes||Mamamlian (human cell)|
|Products description||Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation (501Y.V2 lineage, B.1.351; P.1 lineage, B.18.104.22.168; Kent variant; B.1.526 lineage) was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.|
|Bioactivity validation|| ACE2 binding; |
Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
|Purity||Purity: ≥95% (SDS-PAGE)|
|Application||Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.|
Immunogen in Elisa,lateral-flow tests,and other immunoassays;
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
|predicted Molecular Mass||35kDa|
|Formulation||Lyophilized from sterile PBS, PH 7.4|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|
Recombinant 2019-nCoV(SARS-CoV-2) Spike Protein RBD E484K mutation
(501Y.V2 lineage, B.1.351; P.1 lineage, B.22.214.171.124; Kent variant; B.1.526 lineage)
The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein.
The SARS-CoV-2 (2019nCOV) spike-E484K mutation occurs in different variants and has already been found in the South African variant (B.1.351lineage) and Brazilian variant (B.1.1.28 lineage). On 1st February, Public Health England (PHE) announced that the Covid-19 Genomics (COG-UK) consortium had identified this same E484K mutation in 11 samples carrying the UK variant B.1.1.7 lineage (sometimes called the Kent variant), after analyzing 214 159 sequences. Besides, the E484K mutation also occurs in the B.1.526 lineage that has recently become prevalent in New York State, particularly in the New York City metropolitan area.
|Lineage||The UK variant B.1.1.7 lineage||The South African variant B.1.351 lineage||The Brazilian variant B.1.1.28 lineage||The Kent variant (B.1.1.7 plus E484K)||The New York variant B.1.526 lineage|
|Spike E484K mutation||-||+||+||+||+|
The E484K mutation in the spike protein is located within the receptor-binding domain (RBD). It is called an escape mutation because it helps the virus slip past the body’s immune defenses. Ravindra Gupta at the University of Cambridge and colleagues have confirmed that the new B.1.1.7 plus E484K variant substantially increases the amount of serum antibody needed to prevent infection of cells. The mutation E484K has now been identified in the UK fast-spreading variant, prompting fears the virus is evolving further and could become resistant to vaccines.
Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Validated in functional ELISA, other immunoassays, The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.